HER2 inhibitors

systematic review meta-analysis network meta-analysis

Select advanced breast cancer (metastatic)early breast cancer All type of patientHER2 positive       pertuzumabtrastuzumabtrastuzumab emtansine pertuzumabtrastuzumabtrastuzumab emtansine vs anti-HER2 antibody + taxanesvs endocrine therapy alonevs placebo or control       1st line2nd line2nd+ lineErbB2 positiveHER-2 positiveHR positivepreviously treated by HER-2 antibodypreviously treated by taxanestrastuzumab failure

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	progression or death (progression free survival PFS) (6)death (overall survival) (4) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	progression or death (progression free survival PFS)	death (overall survival)
advanced breast cancer (metastatic)
pertuzumab
CLEOPATRA, 2012          NCT	pertuzumab + trastuzumab +docetaxel	trastuzumab + docetaxel		1st line HER-2 positive	Low risk of bias	suggesting
neoSphere (Group B), 2012      NCT	pertuzumab + trastuzumab +docetaxel	trastuzumab + docetaxel		HER-2 positive	Exploratory	-
trastuzumab
TAnDEM (Kaufman), 2009	trastuzumab + anastrozole	anastrozole alone		HER-2 positive HR positive		-
von Minckwitz, 2009	trastuzumab + capecitabine	capecitabine alone		HER-2 positive previously treated by HER-2 antibody trastuzumab failure		-
Marty, 2005	trastuzumab + docetaxel	docetaxel alone		1st line HER-2 positive		-
Blackwell, 2010	trastuzumab + lapatinib	lapatinib alone		ErbB2 positive previously treated by HER-2 antibody trastuzumab failure		-
Huober, 2012	trastuzumab + letrozole	letrozole alone		HER-2 positive HR positive		-
Gasparini, 2006	trastuzumab + paclitaxel	paclitaxel alone		HER-2 positive		-
Slamon, 2001	trastuzumab + standard chemotherapy	standard chemotherapy alone		HER-2 positive		-
trastuzumab emtansine
EMILIA, 2012      NCT	trastuzumab emtansine	lapatinib plus capecitabine		2nd line HER-2 positive previously treated by HER-2 antibody previously treated by taxanes		suggesting
TH3RESA, 2014    NCT	trastuzumab emtansine	usual care		2nd+ line HER-2 positive previously treated by HER-2 antibody	Risk of bias	suggesting
early breast cancer
pertuzumab
Aphinity    NCT	pertuzumab	placebo			Low risk of bias	-
trastuzumab
NSABP B31, 2005	trastuzumab	control				suggesting
BCIRG006, 2013	trastuzumab	control				suggesting
Buzdar, 2005	trastuzumab	control				suggesting
FinHer, 2006	trastuzumab	control				negative
HERA, 2005	trastuzumab	control				suggesting
N9831, 2005	trastuzumab	control				suggesting
NOAH, 2010	trastuzumab	control				negative
PACS-04, 2009	trastuzumab	control				suggesting
N9831 (1)	trastuzumab	control				suggesting
N9831 (2)	trastuzumab	control				suggesting
FinHer (1)	trastuzumab	control				negative